Concepedia

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Gunilla Enblad, Hannah Karlsson, Gustav Gammelgård, Jessica Wenthe, Tanja Lövgren, Rose‐Marie Amini, Kristina Wikström, Magnus Essand, Barbara Savoldo, Heléne Hallböök,

Clinical Cancer Research · 2018 · 250 citations · 24 references

DOI

Abstract

Third-generation CARs may be efficient in patients with advanced B-cell lymphoproliferative malignancy with only modest toxicity. Immune profiling pre- and posttreatment can be used to find response biomarkers.

References

24

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.7K citations · Full text

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · New England Journal of Medicine · 2014 · 5.3K citations · Full text

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park, Isabelle Rivière, Mithat Gönen et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Richard A. Morgan, James C. Yang, Mio Kitano et al. · Molecular Therapy · 2010 · 2.5K citations · Full text